Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00003362]
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00003362]
Bio2RDF identifier
NCT00003362
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003362
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Vaccines mad ...... age III or stage IV melanoma.
brief title [clinicaltrials_vocabulary:brief-title]
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2001-02-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Evaluate ...... dy within 18-24
months.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
recurrent melanoma
stage III melanoma
stage IV melanoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-06-24T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003362
official title [clinicaltrials_vocabulary:official-title]
Pilot Trial of Multi-Epitope M ...... ntanide and QS-21 as Adjuvants
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2001-02-01T00:00:00Z
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000066345
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1998-05-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-06-01T00:00:00Z
identifier
clinicaltrials:NCT00003362
title
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
@en
type
label
Vaccine Therapy Plus Immune Ad ...... a [clinicaltrials:NCT00003362]
@en